Business
Rakovina Therapeutics Announces Extension of Non-Brokered Private Placement
VANCOUVER, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V...
About this update from Rakovina Therapeutics Inc
[{"type":"text","content":"Rakovina Therapeutics Announces Extension of Non-Brokered Private Placement\nVANCOUVER, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV; FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce that the TSXV has granted the Company a 30-day extension with respect to its non-brokered private placement financing (the “Offering”), previously announced on January 27, 2026 and February 20, 2026. The Offering is now expected to close on or before April 9, 2026, or other such date or dates as determined by the Company and acceptable to the TSXV. As previously disclosed, the Company intends to raise up to $1,000,000 through the Offering as follows: Offering up to 8,333,334 common shares at a price of $0.12 per share for gross proceeds of up to approximately $1.0 million As consideration for services provided in connection with the Common Share Private Placement, the Company may pay a finder’s fee to certain eligible finders who introduce subscribers to the financing. The Company intends to use the net proceeds of the Offering to provide near-term working capital to support ongoing corporate activities and strategic initiatives while the Company continues to evaluate longer-term financing alternatives. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. About Rakovina Therapeutics Inc. Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using validated, proprietary platforms. By using AI, we can review and optimize drug candidates at a much greater pace than ever before. The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Further information may be found at http://www.rakovinatherapeutics.com. Notice Regarding Rakovina Therapeutics Forward-Looking Statements: T...